Maxim Group

Steakholder Foods Ltd is a deep-tech food company focused on revolutionizing protein manufacturing through innovative 3D printing technologies. The company is dedicated to creating sustainable and high-quality alternative meat and seafood products that closely mimic the taste and texture of traditional proteins. By developing proprietary three-dimensional bioprinting techniques, Steakholder aims to improve meat production, streamline the supply chain, and provide consumers with a diverse range of offerings. Its mission includes reducing the environmental impact of food production by minimizing carbon footprints, water usage, and land requirements, while also eliminating the need for animal slaughter. Through its advanced manufacturing solutions, Steakholder Foods is positioning itself as a leader in the plant-based and cultivated meat industry, committed to supporting partners in the rapidly evolving market.

Nacuity Pharmaceuticals is a pharmaceutical company that aims to develop a breakthrough treatment for retinitis pigmentosa (“RP”) and potentially other ophthalmological indications. Nacuity has assembled an accomplished team and has received significant financial and technical support from the Foundation Fighting Blindness (FFB). FFB aims to drive research providing prevention, treatments and cures for people affected by blinding retinal diseases. FFB has invested nearly $700 million in this effort Over the last 46 years. FFB is a significant supporter of Dr. Campochiaro’s research and has committed to fund a substantial portion of Nacuity’s Phase 1 and Phase 2 trials through a milestone-based matching program grant to Nacuity in support of our NPI-001 development program.

Alveo Technologies is focused on developing advanced diagnostic technology to tackle global challenges related to infectious diseases. By leveraging innovations in sensing, microfluidics, and bioassays, the company creates next-generation diagnostic devices that empower consumers and healthcare professionals to detect various diseases more effectively. Their cloud-enabled platform facilitates the generation of extensive datasets, which aids in monitoring infectious disease outbreaks and connecting individuals with appropriate treatments. This approach not only enhances the ability to respond to public health threats but also supports personalized medicine, ultimately leading to improved health outcomes.

Abeona Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing gene and cell therapies for severe, life-threatening rare genetic diseases. The company's leading programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, and ABO-102 and ABO-101, which are AAV-based gene therapies targeting Sanfilippo syndrome types A and B, respectively. Additional therapies under development include ABO-201 and ABO-202 for Batten disease, ABO-401 for cystic fibrosis, and ABO-5OX for genetic eye disorders. Abeona also operates the AIM Vector Platform, which focuses on advancing gene therapy delivery methods using next-generation AAV capsids. The company is engaged in a licensing agreement with REGENXBIO for gene therapies addressing multiple genetic disorders. Founded in 1974 and headquartered in New York, Abeona has a fully operational manufacturing facility that supports its preclinical and clinical research efforts.

Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. EG-1962, our lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. EG-1964, our second product candidate, is being evaluated as a potential prophylactic treatment in the management of chronic subdural hematoma, to prevent recurrent bleeding on the surface of the brain. It was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.

ContraFect is a biotechnology company pioneering the use of monoclonal antibodies to treat life-threatening infectious diseases. It addresses multi-drug resistant infections using therapeutic products from its lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. Its novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills bacteria. The company was founded in 2008 and is headquartered in Yonkers, New York.

BillMyParents delivers SuperSafe payment solutions that allow teens greater financial freedom, while giving parents the ability to easily track and control their spending. BillMyParents Supervised Shopping - With a simple email request and approval system, provides the independence young people crave and the control over spending that parents want - while ensuring that credit card numbers and personal information are kept safe and secure. BillMyParents is currently available as a payment solution at select online retail stores, in addition to social network, virtual worlds and online gaming web sites. The teen prepaid MasterCard extends BillMyParents into the offline world, the BillMyParents MasterCard Prepaid Card is accepted anywhere MasterCard debit cards are accepted and offers teens more options than ever before, meanwhile it provides advanced parental controls and spending insight that makes it a far superior option for parents than giving cash or sharing their own credit card information for purchases. Its Peace of Mind Control Panel provides the following parental benefits: - The ability to monitor transactions in real-time via email and/or SMS notifications - Instant lock / unlock of their teen’s card - Instant emergency funding for the teen — so they are never stranded without access to money in an emergency - Lost card protection (losing the card doesn’t lose the value on the card) - No credit implications for parents or their teens - No overdraft fees!